Loading...
Market
What will be the approval status of Capvaxive in major international markets by the end of 2024?
1
Resolution / Starting Odds
Approved in all major markets • 25%
Approved in some major markets • 25%
Not approved in any major markets • 25%
Approval status pending • 25%
Regulatory bodies' announcements in major international markets (e.g., EMA, Health Canada, TGA)
Story
FDA Approves Merck's 21-Valent Pneumococcal Vaccine Capvaxive for Adults
Jun 17, 2024, 09:24 PM
The U.S. Food and Drug Administration (FDA) has approved Merck's new 21-valent pneumococcal vaccine, Capvaxive, designed to protect adults against 21 strains of pneumococcus bacteria. This vaccine targets eight serotypes of Streptococcus pneumoniae that are not covered by existing pneumococcal vaccines. The approval sets the stage for a competitive battle between Merck and Pfizer in the pneumococcal vaccine market. The vaccine aims to protect against invasive pneumococcal disease and pneumonia. The Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC) will provide recommendations on its usage next week.
View original story
Similar markets
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
<10% • 25%
10-20% • 25%
20-30% • 25%
>30% • 25%
Pfizer • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Other • 25%
Yes • 50%
No • 50%
<$300 million • 25%
$300-500 million • 25%
$500-700 million • 25%
>$700 million • 25%
Approved in UK only • 25%
Approved in UK and EU • 25%
Approved in UK, EU, and USA • 25%
Not approved in any major market • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%